ECSP045345A - Tratamiento de la gastroparesia - Google Patents

Tratamiento de la gastroparesia

Info

Publication number
ECSP045345A
ECSP045345A EC2004005345A ECSP045345A ECSP045345A EC SP045345 A ECSP045345 A EC SP045345A EC 2004005345 A EC2004005345 A EC 2004005345A EC SP045345 A ECSP045345 A EC SP045345A EC SP045345 A ECSP045345 A EC SP045345A
Authority
EC
Ecuador
Prior art keywords
gastroparesia
treatment
glp
patients
compounds
Prior art date
Application number
EC2004005345A
Other languages
English (en)
Inventor
Joseph Anthony Jakubowski
Thurman Dwight Mckinney
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP045345A publication Critical patent/ECSP045345A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere al uso de compuestos de GLP-1 para tratar la gastroparesia. Los pacientes con gastroparesia experimentan generalmente un retraso en el vaciado gástrico. Los compuestos de GLP-1 se pueden usar para regular el vaciado gástrico en estos pacientes.
EC2004005345A 2002-04-10 2004-10-08 Tratamiento de la gastroparesia ECSP045345A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37165002P 2002-04-10 2002-04-10

Publications (1)

Publication Number Publication Date
ECSP045345A true ECSP045345A (es) 2006-04-19

Family

ID=29250714

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005345A ECSP045345A (es) 2002-04-10 2004-10-08 Tratamiento de la gastroparesia

Country Status (18)

Country Link
US (1) US20050164925A1 (es)
EP (1) EP1496924A4 (es)
JP (1) JP2005530732A (es)
KR (1) KR20040098063A (es)
CN (1) CN1735423A (es)
AU (1) AU2003220403A1 (es)
BR (1) BR0308904A (es)
CA (1) CA2480858A1 (es)
EA (1) EA200401345A1 (es)
EC (1) ECSP045345A (es)
HR (1) HRP20040939A2 (es)
IL (1) IL164266A0 (es)
MX (1) MXPA04009929A (es)
NO (1) NO20044815L (es)
NZ (1) NZ535684A (es)
PL (1) PL373658A1 (es)
WO (1) WO2003087139A2 (es)
ZA (1) ZA200408111B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8666495B2 (en) 1999-03-05 2014-03-04 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
US9101765B2 (en) 1999-03-05 2015-08-11 Metacure Limited Non-immediate effects of therapy
US8792985B2 (en) 2003-07-21 2014-07-29 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
WO2005028516A2 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
AU2004273573B2 (en) * 2003-09-19 2010-04-22 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
ATE532459T1 (de) 2004-08-18 2011-11-15 Metacure Ltd Überwachung, analyse und regulierung von essgewohnheiten
US9821158B2 (en) 2005-02-17 2017-11-21 Metacure Limited Non-immediate effects of therapy
US9339190B2 (en) 2005-02-17 2016-05-17 Metacure Limited Charger with data transfer capabilities
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
JP5755398B2 (ja) 2005-03-18 2015-07-29 ノヴォ ノルディスク アー/エス 伸長されたglp−1化合物
US8265758B2 (en) * 2005-03-24 2012-09-11 Metacure Limited Wireless leads for gastrointestinal tract applications
US8463404B2 (en) 2005-03-24 2013-06-11 Metacure Limited Electrode assemblies, tools, and methods for gastric wall implantation
EP1890763A4 (en) 2005-06-02 2017-05-03 Metacure Limited Gi lead implantation
US8442841B2 (en) * 2005-10-20 2013-05-14 Matacure N.V. Patient selection method for assisting weight loss
US8295932B2 (en) 2005-12-05 2012-10-23 Metacure Limited Ingestible capsule for appetite regulation
EP2573111A1 (en) * 2006-04-20 2013-03-27 Amgen Inc. GLP-1 compounds
AU2012203915B9 (en) * 2006-04-20 2014-10-09 Amgen Inc. GLP-1 compounds
US8417329B2 (en) * 2007-05-09 2013-04-09 Metacure Ltd. Analysis and regulation of food intake
US8423130B2 (en) * 2008-05-09 2013-04-16 Metacure Limited Optimization of thresholds for eating detection
KR20110039348A (ko) 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
JP5816097B2 (ja) 2009-01-22 2015-11-18 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
JP6086528B2 (ja) 2009-08-06 2017-03-01 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 長期のインビボ有効性を有する成長ホルモン
EP2482840A4 (en) * 2009-08-07 2013-06-26 Mannkind Corp VAL (8) GLP-1 COMPOSITION AND METHOD FOR THE TREATMENT OF REAGENTS AND / OR IRRITATION SYNDROME
JP5980689B2 (ja) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
RS59459B1 (sr) 2010-01-22 2019-11-29 Novo Nordisk Healthcare Ag Hormoni rasta sa produženom in-vivo efikasnošću
WO2011092710A2 (en) * 2010-02-01 2011-08-04 Metacure Limited Gastrointestinal electrical therapy
BR112012027893A2 (pt) 2010-04-30 2019-09-24 Sanwa Kagaku Kenkyusho Ltd peptídeo para aumento da bioestabilidade de substância bioativa e substância biotiva que possui bioestabilidade aumentada.
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
EP2934569A1 (en) 2012-12-21 2015-10-28 Sanofi Exendin-4 derivatives
WO2014166836A1 (en) 2013-04-05 2014-10-16 Novo Nordisk A/S Growth hormone compound formulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
JP2002510193A (ja) * 1997-03-31 2002-04-02 イーライ・リリー・アンド・カンパニー グルカゴン様ペプチド−1類似体
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand

Also Published As

Publication number Publication date
JP2005530732A (ja) 2005-10-13
NO20044815L (no) 2005-01-07
EP1496924A4 (en) 2007-05-30
CA2480858A1 (en) 2003-10-23
HRP20040939A2 (en) 2004-12-31
NZ535684A (en) 2006-03-31
ZA200408111B (en) 2005-10-07
WO2003087139A3 (en) 2004-01-08
EP1496924A2 (en) 2005-01-19
IL164266A0 (en) 2005-12-18
WO2003087139A2 (en) 2003-10-23
MXPA04009929A (es) 2006-03-10
AU2003220403A1 (en) 2003-10-27
KR20040098063A (ko) 2004-11-18
CN1735423A (zh) 2006-02-15
EA200401345A1 (ru) 2005-08-25
BR0308904A (pt) 2005-05-03
PL373658A1 (en) 2005-09-05
US20050164925A1 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
ECSP045345A (es) Tratamiento de la gastroparesia
ATE461217T1 (de) Glp-1-verbindungen
PA8534601A1 (es) Activadores de glucocinasa del tipo isoindolin-1-ona
EA200601747A1 (ru) Три(цикло)замещённые амидные соединения
EP1804804A4 (en) LOXAPINE ANALOGUES AND METHODS OF USE
TW200701982A (en) Novel use of peptide compounds for treating pain in trigeminal neuralgia
MX2008002293A (es) Uso novedoso de compuestos peptidicos para tratar dolor muscular.
ECSP055840A (es) Derivados de 4 -tetrazolil-4fenilpiperidina para el tratamiento del dolor
ECSP056210A (es) Preparación y uso de derivados de alquilarilo para el tratamiento de la obesidad
EP1490044A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMABLE COMPONENTS
IS2517B (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
BRPI0512622A (pt) uso de compostos de peptìdeos para tratamento de tremor e outras sìndromes de tremor
NO20054371L (no) Somatostatin-dopamin kimaere analoger
UY28150A1 (es) Agentes terapeuticos
UY26130A1 (es) Compuestos para tratar la obesidad
ECSP034810A (es) Derivados heterociclilalcoxi-, -alquiltio- y - alquilaminobenzazol tales como ligandos 5-hidroxitriptamina-6
HK1077755A1 (en) Use of a paralpha agonist and metformin for the treatment of obesity ppar-alpha
DE60026146D1 (de) Verwendung von dapoxetin, a selektiver serotonin-aufnahme inhibitor mit schnellem wirkungseintritt, zur behandlung von sexueller dysfunction
UY27244A1 (es) Uso del acido- (4´-trifluormetilfenil) - amida (z) -2- ciano-3- hidroxi-but-2-enoico para el tratamiento de la esclerosis multiple
HN2002000110A (es) Uso de (z) - 2 - ciano - 3 - hidroxi - butil - 2 - acido enoico (4' - trifluorometil fenilo) - amida para el tratamiento de la esclerosis multiple.
UY27203A1 (es) Bencimidazoles útiles en el tratamiento de la disfunción sexual
MXPA05001885A (es) El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica.
PT1030667E (pt) Utilizacao de mirtazapina para o fabrico de um medicamento para o tratamento de apenas do sono
DK1532131T3 (da) Motilid-forbindelser
TW200628168A (en) Use of organic compounds